Form 4: iTeos Therapeutics CEO Michel Detheux Executes Pre-Planned Stock Option Exercises and Share Sales

iTeos Therapeutics CEO Michel Detheux executed a series of pre-planned transactions, exercising stock options at $4.30 and subsequently selling shares at weighted average prices between $10.10 and $10.21, both directly and indirectly through a related entity.

Summary

• Michel Detheux, Chief Executive Officer of iTeos Therapeutics, Inc. (ITOS), engaged in a series of pre-planned transactions from June 4 to June 6, 2025, under a Rule 10b5-1 trading plan adopted on March 5, 2025.
• On each of June 4, 5, and 6, 2025, Mr. Detheux directly acquired 8,400 shares of Common Stock by exercising stock options at an exercise price of $4.30 per share.
• Concurrently, on each of June 4, 5, and 6, 2025, Mr. Detheux directly disposed of 8,400 shares of Common Stock.
• The direct sales occurred at weighted average prices of $10.10 (June 4), $10.15 (June 5), and $10.21 (June 6), with prices ranging from $10.00 to $10.31 across the three days.
• Indirectly, through MG3A (a Belgian partnership managed by Mr. Detheux), 43,883 shares were acquired on June 4, 2025, and 43,882 shares on both June 5 and June 6, 2025, by exercising stock options at $4.30 per share.
• Correspondingly, MG3A disposed of 43,883 shares on June 4, 2025, and 43,882 shares on both June 5 and June 6, 2025.
• The indirect sales through MG3A occurred at weighted average prices of $10.10 (June 4), $10.15 (June 5), and $10.21 (June 6), with prices ranging from $10.01 to $10.31 across the three days.
• Following these transactions, Mr. Detheux's direct beneficial ownership of Common Stock is 135,903 shares, while indirect beneficial ownership through MG3A is 0 shares of Common Stock.
• The number of directly held stock options decreased from 51,600 to 34,800, and indirectly held stock options decreased from 269,559 to 181,795.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by the CEO. While the transactions were pre-planned under a Rule 10b5-1 plan, which reduces the severity of the negative signal, the sheer volume of shares sold (including the complete liquidation of indirect common stock holdings) can still be perceived as a lack of strong conviction in the company's immediate stock price trajectory by a key executive.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, adopted on March 5, 2025, which indicates the sales were not based on immediate, non-public information.
• The exercise price of the stock options ($4.30) is significantly lower than the sale prices (ranging from $10.00 to $10.31), indicating a profitable exercise for the CEO.

Negatives

• The CEO engaged in significant insider selling, disposing of a total of 156,847 shares (both directly and indirectly) over three days.
• The sales reduced the CEO's direct common stock holdings and completely liquidated the indirect common stock holdings through MG3A, potentially signaling a reduction in personal exposure to the company's equity.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025.

Industry Context

This Form 4 filing details routine insider transactions (option exercises and subsequent share sales) by a senior executive. Such filings are common across all industries, particularly in biotechnology where executive compensation often includes significant equity components. The execution under a 10b5-1 plan is a standard practice to manage insider trading compliance.

Related Party Transactions

• Transactions were conducted indirectly through MG3A, which is identified as a Belgian partnership where the reporting person (Michel Detheux) is the manager and his spouse is the successor manager. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the significant insider selling by the CEO as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.
• Employees may observe the executive's share sales, which could influence their perception of the company's short-term outlook.

Key Dates

Recommendation

Keywords

iTeos Therapeutics, ITOS, Michel Detheux, CEO, Form 4, insider trading, stock options, share sale, 10b5-1 plan, beneficial ownership, biotechnology, pharmaceuticals